ArticleFrontiers in pharmacology2025
Distinct neuroprotective and anti-inflammatory effects of Kampo formulas ninjinyoeito and juzentaihoto in depression-like SAMP8 mice.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The IR-Homeostat Hypothesis: Intron Retention as an Evolutionarily Conserved Fine-Tuning Layer and a Reversible Blood Biomarker of Homeostatic Dysregulation in Mood Disorders.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In contemporary aging societies, preventing and ameliorating mental and physical frailty is essential. Kampo formulas, including ninjinyoeito (NYT) and juzentaihoto (JTT), have been used traditionally to treat frailty in the elderly. NYT has been reported to alleviate psychological frailty such as depression and anxiety. This study aimed to clarify the mechanisms underlying the effects of these two Kampo formulas in the early stages of neurodegeneration associated with psychiatric disorders. Methods: Genes affected by Kampo formulas were comprehensively investigated by administering JTT or NYT to senescence accelerated mouse prone 8 (SAMP8) mice, from 7 weeks, and by RNA sequencing of the hippocampus at 19 weeks when depression and anxiety behaviors typically emerge. Additionally, we examined the impact of these Kampo formulas on neuroinflammation induced by lipopolysaccharide (LPS). Results: The two Kampo formulas alleviated the depressive-like behavior of SAMP8 mice, as demonstrated by the restoration of microglial cell activation, DNA repair, stress-responsive transcription factor expression, and nervous system development-related gene expression. However, the NYT-administrated group presented a greater number of recovered genes than did the JTT-administrated group, and NYT additionally suggests that the potential inhibition of age-related mitochondrial dysfunction and increased oxidative stress. The administration of LPS resulted in elevated expression levels of immune and inflammation-related genes and increased astrocyte activity in SAMP8 mice. JTT mitigated these effects by suppressing the expression of the LPS receptor TLR4 and its downstream target NF-κB. In contrast to JTT, NYT maintained and increased the expression of genes associated with neuroprotective functions in microglia. Discussion: The two Kampo formulas exerted neuroprotective effects by enhancing neural and glial stress responses in the early stages of neurodegeneration. Under condition of acute inflammation, JTT and NYT alleviated neuronal damage via the suppression of microglial activity and the enhancement of microglial neuroprotection, respectively. These findings provide novel insights into the mechanism of action of NYT, which has been reported to ameliorate psychological frailty associated with aging, and further suggest that JTT may exert effects against inflammatory neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.